MedTrace Logo

A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

NCT00831103 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 373

Last updated 2013-12-05

No results posted yet for this study

Summary

The purpose of this study is to determine the pharmacokinetics and dosage of EPB-348 that best balances safety and efficacy among adult immunocompetent patients with an acute episode of herpes zoster.

Conditions

  • Herpes Zoster

Interventions

DRUG

EPB-348

Treated over seven days

DRUG

Valacyclovir

Treated over seven days

Sponsors & Collaborators

  • Epiphany Biosciences

    lead INDUSTRY

Principal Investigators

  • Stephen K Tyring, MD · University of Texas Health Science Center, Houston, Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831103 on ClinicalTrials.gov